The tender period for acquiring all outstanding shares of Day One Biopharmaceuticals is scheduled to lapse one minute after 11:59 p.m. ET on 22nd April 2026. This deadline is subject to potential extensions or earlier termination, as is standard practice in such corporate transactions. Following this, a merger between Servier and Day One Bio is tentatively slated to finalise just before the market opens on 23rd April 2026.
Shareholders need to note that trading in DAWN stock will be halted significantly before the merger's targeted closure. The suspension of trading is planned to occur immediately after the after-hours session on 22nd April 2026, around 7:50 p.m. ET. This means that the last opportunity for investors to trade Day One Biopharmaceuticals shares on the open market would be earlier on this date.
Should the merger proceed as intended, the stock will remain halted throughout the entire trading day of 23rd April 2026. This ensures a smooth transition and prevents any last-minute trading activity that could complicate the acquisition process. Subsequently, the shares will be officially suspended from the marketplace, effective from 24th April 2026.
The CUSIP number for Day One Biopharmaceuticals, Inc. Common Stock is 23954D109, with the ticker symbol DAWN. The anticipated last trading date for DAWN shares is 22nd April 2026. The marketplace effective date for suspension is pencilled in for 24th April 2026.
Under the terms of the tender offer, shareholders of Day One Biopharmaceuticals will receive $21.50 for each share they hold. This cash consideration represents the acquisition price agreed upon for the takeover by Servier. Investors should consult their brokers or financial advisors for specific guidance regarding their holdings in light of these developments.
This corporate action represents a significant event for Day One Biopharmaceuticals shareholders and the wider biotech investment community, marking the potential integration of the company into Servier's portfolio.
